WX-G250 (known also as girentuximab), the first CA-IX inhibitor to enter clinical trials [162], is another chimeric monoclonal antibody that is actually in phase III clinical trials, as an adjuvant therapy for the treatment of non-metastasized renal cell carcinoma. This evidence concerns the gene CA9 and hereditary clear cell renal cell carcinoma.